U.S., Nov. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07919028) titled 'A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006)' on Oct. 30.
Brief Summary: MK-7602 is a new medicine that is being studied to treat malaria. Malaria is a disease caused by a parasite that spreads to people through mosquito bites. Symptoms of malaria include fever, chills, and flu-like illness. If malaria is not treated, some people can have serious problems that can be deadly.
The goal of this trial is to learn what happens to MK-7602 in a person's body over time (a pharmacokinetic or PK trial). Researchers will compare what happens to MK-7602 in people's blood when it is taken alone (Period 1) and in combination wi...